News

FA is a life-shortening and degenerative neuro-muscular disorder that affects nearly 4,000 to 6,000 people in the US. The placebo-controlled trial, Steadfast, failed to demonstrate that Actimmune therapy resulted

Duke will receive an undisclosed upfront payment from Sermonix, as well as future equity and milestone payments. Sermonix also announced that it secured more than $2 million in a

This decision is supported by the most recent data from the Company's ongoing Phase 1b study evaluating the same "triplet combination" therapy being investigated in the amended Phase

Lucentis (ranibizumab) has now been cleared to treat patients for visual impairment due to CNV associated with causes other than neovascular age-related macular degeneration (nAMD) or secondary to

The study found that patients with ALK+ advanced NSCLC treated with first-line Zykadia (ceritinib) had a median progression-free survival (PFS) of 16.6 months (95% confidence interval [CI]: 12.6, 27.2), compared to

Women are said to have a ‘platinum-sensitive’ form of the disease if a relapse occurs six months or longer following the last treatment with a platinum-based chemotherapy. Genentech

Velusetrag is an oral investigational drug in development for the treatment of patients with gastroparesis, and is currently being studied in a large, multinational Phase 2b study in

The Competition and Markets Authority (CMA) fined Pfizer £84.2m and Flynn Pharma £5.2m after they increased prices by as much as 2,600% in September 2012. Due to the price increases, the

Results from the first randomised Phase III data showed that Tagrisso reduced the risk of lung cancer progression by 70% compared to chemotherapy and improved progression-free survival (PFS)